Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Rated "Moderate Buy" by Sell-Side Analysts

Design Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Design Therapeutics a “Moderate Buy” consensus: Of nine analysts, seven rate the stock a buy, one a strong buy, and one a sell; the average 12-month price target is $18.57.
  • The stock opened at $9.47, below its 50-day and 200-day moving averages, and has traded between $7.25 and $17.25 over the past year.
  • Design Therapeutics reported a quarterly loss of $0.32 per share, slightly better than the $0.34 loss analysts expected. Institutional investors own 56.64% of the company’s shares.
  • MarketBeat previews the top five stocks to own by December 1st.

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $18.57.

DSGN has been the subject of a number of research reports. Wells Fargo & Company assumed coverage on Design Therapeutics in a research report on Friday, October 2nd. They set an "overweight" rating and a $26.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Design Therapeutics in a report on Thursday, October 15th. Wall Street Zen lowered shares of Design Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, November 7th. Finally, Royal Bank Of Canada decreased their price target on shares of Design Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Thursday, November 5th.

Get Our Latest Report on Design Therapeutics

Design Therapeutics Stock Performance

NASDAQ DSGN opened at $9.47 on Thursday. The firm's 50 day moving average price is $11.36 and its two-hundred day moving average price is $12.15. The stock has a market cap of $606.42 million, a price-to-earnings ratio of -7.89 and a beta of 1.73. Design Therapeutics has a twelve month low of $7.25 and a twelve month high of $17.25.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. On average, research analysts forecast that Design Therapeutics will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Design Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. J. Goldman & Co LP purchased a new stake in shares of Design Therapeutics during the 2nd quarter worth about $2,558,000. Bank of New York Mellon Corp acquired a new stake in shares of Design Therapeutics during the 2nd quarter valued at about $1,332,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Design Therapeutics in the 2nd quarter valued at approximately $26,189,000. Dimensional Fund Advisors LP grew its stake in shares of Design Therapeutics by 45.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 431,840 shares of the company's stock valued at $4,593,000 after buying an additional 133,919 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Design Therapeutics by 42.2% in the first quarter. Renaissance Technologies LLC now owns 408,200 shares of the company's stock worth $4,343,000 after buying an additional 121,100 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.

About Design Therapeutics

(Get Free Report)

Design Therapeutics is a clinical-stage biotechnology company developing medicines for inherited diseases. Its research focuses on conditions associated with genetic repeat expansions, in which repeated DNA sequences can disrupt the normal activity of a gene. The company's GeneTAC platform is designed to create small molecules that interact with these expanded genetic sequences and help restore gene expression. Design Therapeutics aims to use this approach to address the underlying causes of disease rather than only manage symptoms.

Featured Articles

Analyst Recommendations for Design Therapeutics (NASDAQ:DSGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Design Therapeutics Right Now?

Before you consider Design Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.

While Design Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines